MDxHealth, Plus Diagnostics to Co-promote Epigenetic Prostate Cancer Test | GenomeWeb

NEW YORK (GenomeWeb News) – MDxHealth and Plus Diagnostics today announced a co-promotional deal covering MDxHealth's epigenetic test for prostate cancer in the US.

Plus Diagnostics will build awareness for MDx Health's ConfirmMDx test through its national network of urologists. Financial and other terms of the deal were not disclosed.

"The national reach afforded by Plus Diagnostics provides a direct channel to the urology community and will aid in meeting the growing demand for our test," MDxHealth CEO Jan Groen said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.